SCHEMBL14770471

SCHEMBL14770471

CCOc1ccc2[nH]c(C(O)c3ccc(OC)cc3)nc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.55
▸ HTT P42858 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ MLKL Q8NB16 2/20 0.46
▸ CHEK2 O96017 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ HPGD P15428 3/20 0.39
▸ MAPT P10636 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ ESR2 Q92731 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ TSHR P16473 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ PDE10A Q9Y233 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770690 0.90 MLKL (0.52) MEN1HTTKMT2AMLKLCHEK2
SCHEMBL14770535 0.86 MEN1 (0.53) MEN1HTTKMT2AL3MBTL1ALDH1A1
SCHEMBL12066005 0.86 MEN1 (0.51) MEN1HTTKMT2AMLKLL3MBTL1
SCHEMBL14770719 0.86 MEN1 (0.48) MEN1HTTKMT2AMLKLALDH1A1
SCHEMBL14770491 0.84 KMT2A (0.51) MEN1HTTKMT2AMLKLL3MBTL1
SCHEMBL14770701 0.84 MLKL (0.49) MEN1HTTKMT2AMLKLCHEK2
SCHEMBL12066577 0.84 MLKL (0.59) MEN1HTTKMT2AMLKLCHEK2
SCHEMBL14770699 0.83 MLKL (0.46) MEN1HTTKMT2AMLKLCHEK2
SCHEMBL14770697 0.82 MLKL (0.51) MEN1KMT2AMLKLCHEK2TSHR
SCHEMBL14770608 0.82 MLKL (0.48) MEN1HTTKMT2AMLKLCHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 — — US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A MEN1 2676/4885HTT 3959/4885KMT2A 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback